| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 38,579 | - |
| Discovery department expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 12,712 | - |
| Development department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 47,302 | - |
| General and administrative expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 17,502 | - |
| Employee wages and benefits - discovery | 6,949 | - |
| Employee wages and benefits - development | 15,406 | - |
| Employee wages and benefits - general and administrative | 11,207 | - |
| Stock-based compensation expense | 35,273 | - |
| Other segment items | -151 | - |
| Interest income | 22,028 | - |
| Income tax benefit (expense) | 172 | - |
| Net (loss) income | -85,765 | -46,426 |
| Stock-based compensation | 35,273 | 24,714 |
| Non-cash lease expense | 1,243 | 1,137 |
| Depreciation | 904 | 543 |
| Accretion of discount on marketable securities | 5,887 | 4,203 |
| Net realized loss on sale of marketable securities | -4 | -5 |
| Receivable from collaboration partner | -164,417 | -165,000 |
| Prepaid expenses and other assets | 1,995 | 2,045 |
| Accounts payable | 4,030 | 1,612 |
| Contract asset | - | 22,287 |
| Accrued expenses and other payables | -833 | -8,378 |
| Income taxes payable | -2,689 | -2,689 |
| Deferred revenue | -13,579 | -10,504 |
| Operating lease liability | -477 | 104 |
| Net cash provided by operating activities | 94,646 | 96,583 |
| Purchase of marketable securities | 442,311 | 281,194 |
| Proceeds from maturities of marketable securities | 338,607 | 235,957 |
| Proceeds from sale of marketable securities | 7,003 | 7,003 |
| Purchases of property and equipment | 1,446 | 1,358 |
| Net cash used in investing activities | -98,147 | -39,592 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 20,506 | 14,847 |
| Tax withholding payments related to net settlement of restricted stock units | 479 | 479 |
| Net cash provided by financing activities | 20,027 | 14,368 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16,526 | 71,359 |
| Cash and cash equivalents at beginning of period | 97,474 | - |
| Cash and cash equivalents at end of period | 114,000 | - |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)